Hopkins KD, Gollogly L, Ogden S, Horton R. Strange results mean it's worth checking ISI data. Nature 2002 Feb 14; 415(6873): 732.
Over a period of several years, I spent many hours analysing data used to calculate The Lancet's Impact Factor. This letter in Nature was intended to alert others to flaws in ISI's (now Thomson Reuters) methodology.
Passey S. Cholesterol control might help treat Alzheimer's disease. Lancet Neurol 2004; 3(12): 700.
Passey S. Gene mutation detected in Parkinson's disease. Lancet Neurol 2005; 4(3): 142-43.
Passey S. Family members have final say in treatment decisions. Lancet Oncol 2006; 7(2): 113.
Passey S. Endostatin gene therapy inhibits tumour growth. Lancet Oncol 2006; 7(3): 199.
Passey S. Media watch: The Human Mind. Lancet Neurol 2004; 3(2): 131.
In 2003, I worked on The Lancet's end-of-year special issue, Extreme Medicine. This issue covered topics from extreme solutions to rare diseases, and addressed the suffering caused by wars, plagues, and political turmoil.
In 2005, I edited and sourced illustrations for The Lancet's Epidemiology series.